source
- Summit Therapeutics' ivonescimab shows improved survival trend in extended follow-up, easing investor doubtsA new analysis of Summit Therapeutics and Akeso's dual‑acting cancer immunotherapy ivonescimab indicates that the drug's impact on overall survival has grown with longer observation. The extended d…
- Hospital AI oversight lagging; senior leaders must take daily responsibilityAI tools are now common in U.S. hospitals, handling tasks such as drafting clinical notes, flagging sepsis, screening imaging, processing prior authorizations, and responding to patient messages.…